MA52889A - Augmentation de l'activité immunitaire par modulation de facteurs de signalisation post-cellulaires - Google Patents

Augmentation de l'activité immunitaire par modulation de facteurs de signalisation post-cellulaires

Info

Publication number
MA52889A
MA52889A MA052889A MA52889A MA52889A MA 52889 A MA52889 A MA 52889A MA 052889 A MA052889 A MA 052889A MA 52889 A MA52889 A MA 52889A MA 52889 A MA52889 A MA 52889A
Authority
MA
Morocco
Prior art keywords
modulation
post
cellular signaling
immune activity
increased immune
Prior art date
Application number
MA052889A
Other languages
English (en)
Inventor
Anthony Michael Barsotti
Alexandra Masu Cantley
Jason Park
Original Assignee
Flagship Pioneering Innovations V Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flagship Pioneering Innovations V Inc filed Critical Flagship Pioneering Innovations V Inc
Publication of MA52889A publication Critical patent/MA52889A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
MA052889A 2018-06-15 2019-06-14 Augmentation de l'activité immunitaire par modulation de facteurs de signalisation post-cellulaires MA52889A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862685770P 2018-06-15 2018-06-15
US201862781819P 2018-12-19 2018-12-19

Publications (1)

Publication Number Publication Date
MA52889A true MA52889A (fr) 2021-04-21

Family

ID=67138105

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052889A MA52889A (fr) 2018-06-15 2019-06-14 Augmentation de l'activité immunitaire par modulation de facteurs de signalisation post-cellulaires

Country Status (9)

Country Link
US (1) US20210251994A1 (fr)
EP (1) EP3806848A2 (fr)
JP (1) JP2021528393A (fr)
KR (1) KR20210035805A (fr)
CN (1) CN112638375A (fr)
AU (1) AU2019287765A1 (fr)
CA (1) CA3103629A1 (fr)
MA (1) MA52889A (fr)
WO (1) WO2019241730A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3915585A1 (fr) * 2020-05-26 2021-12-01 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Combinaisons thérapeutiques comprenant des agonistes de la ferroptose pour le traitement de troubles prolifératifs
CN113421613B (zh) * 2021-06-08 2024-06-18 吴安华 一种基于铁死亡水平评价胶质母细胞瘤患者免疫治疗反应性的系统及分析方法
US11541116B1 (en) 2022-01-07 2023-01-03 Kojin Therapeutics, Inc. Methods and compositions for inducing ferroptosis in vivo
CN117625547B (zh) * 2022-08-25 2024-06-28 广州百吉生物制药有限公司 联合表达gpx4的新一代嵌合抗原受体及其应用
CN115804772B (zh) * 2022-11-16 2024-04-26 山东大学 一种铁死亡抑制剂在抗病毒感染中的应用
CN119552124A (zh) * 2023-09-04 2025-03-04 上海深势唯思科技有限责任公司 一种芳基杂环类slc7a11抑制剂及其制备方法和用途

Family Cites Families (243)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR104E (fr)
US5843708A (en) 1988-01-05 1998-12-01 Ciba-Geigy Corporation Chimeric antibodies
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
DE19939653A1 (de) 1999-08-13 2001-02-22 Thomas Huenig Verwendung CD28 spezifischer monoklonaler Antikörper zur Herstellung einer pharmazeutischen Zusammensetzung
JP3871503B2 (ja) 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
JP4210454B2 (ja) 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
DE60035057T2 (de) 1999-10-04 2008-01-31 Novartis Vaccines and Diagnostics, Inc., Emeryville CD40 Antagonist zur Behandlung von Psoriasis
EP1261376A1 (fr) 2000-01-27 2002-12-04 Genetics Institute, LLC Anticorps contre ctla4 (cd152), conjugues comprenant lesdits anticorps, et leurs utilisations
BR0110190A (pt) 2000-04-19 2003-12-30 Tanox Inc Antagonistas de cd40 para uso em tratamento de psorìase e outras condições inflamatórias de pele
US20030059427A1 (en) 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
JP3597140B2 (ja) 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
WO2002028905A2 (fr) 2000-10-02 2002-04-11 Chiron Corporation Anticorps humains anti-cd40
DE10050935A1 (de) 2000-10-11 2002-05-02 Tegenero Gmbh Verwendung CD28 spezifischer monoklonaler Antikörper zur Stimulation von Blutzellen, welche kein CD28 tragen
US8501471B2 (en) 2000-10-18 2013-08-06 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8H9
WO2003075846A2 (fr) 2002-03-08 2003-09-18 Sloan-Kettering Institute For Cancer Research Utilisations d'anticorps 8h9 monoclonaux
US8414892B2 (en) 2000-10-18 2013-04-09 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8H9
US20020102264A1 (en) 2000-10-18 2002-08-01 Cheung Nai-Kong V. Uses of monoclonal antibody 8H9
CA2423843A1 (fr) 2000-10-18 2002-04-25 Sloan-Kettering Institute For Cancer Research Utilisations d'anticorps monoclonal 8h9
CN1272345C (zh) 2000-12-14 2006-08-30 安斯泰来制药有限公司 沉默型抗cd－28抗体及其应用
ES2353273T3 (es) 2000-12-26 2011-02-28 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anticuerpos anti-cd28.
AR036993A1 (es) 2001-04-02 2004-10-20 Wyeth Corp Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
EP2011802A3 (fr) 2001-04-27 2009-04-15 Kyowa Hakko Kirin Co., Ltd. Anticorps monoclonal anti-CD40
WO2003029296A1 (fr) 2001-10-02 2003-04-10 Chiron Corporation Anticorps humains diriges contre le cd40
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
AU2002346581A1 (en) 2001-11-26 2003-06-10 Chiron Corporation Antagonist anti-cd40 monoclonal antibody therapy for multiple sclerosis treatment
US20080199471A1 (en) 2002-03-01 2008-08-21 Bernett Matthew J Optimized cd40 antibodies and methods of using the same
DE10212108A1 (de) 2002-03-13 2003-10-02 Tegenero Ag Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung
NZ536746A (en) 2002-06-13 2007-02-23 Crucell Holland Bv An agonistic antibody or fragment thereof that immunospecifically binds and stimulates the human OX40-receptor
DE10230223A1 (de) 2002-07-04 2004-01-22 Tegenero Ag Mikropartikel mit CD28-spezifischen monoklonalen Antikörpern
US7052694B2 (en) 2002-07-16 2006-05-30 Mayo Foundation For Medical Education And Research Dendritic cell potentiation
US6693136B1 (en) 2002-07-26 2004-02-17 Abbott Laboratories Fluorenes and anthracenes that inhibit P2X3 and P2X2/3 containing receptors
AU2003259294A1 (en) 2002-07-30 2004-02-16 Bristol-Myers Squibb Company Humanized antibodies against human 4-1bb
US7291331B1 (en) 2002-09-11 2007-11-06 La Jolla Institute For Allergy And Immunology Methods of treating OX40 medicated recall immune responses
WO2004056875A1 (fr) 2002-12-23 2004-07-08 Wyeth Anticorps anti pd-1 et utilisations
US20070104688A1 (en) 2003-02-13 2007-05-10 City Of Hope Small interfering RNA mediated transcriptional gene silencing in mammalian cells
AU2004244626A1 (en) 2003-05-23 2004-12-09 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services GITR ligand and GITR ligand-related molecules and antibodies and uses thereof
US20090191213A9 (en) 2003-07-02 2009-07-30 Novo Nordisk A/S Compositions and methods for regulating NK cell activity
EP1600164A3 (fr) 2003-09-22 2006-05-17 TeGenero AG Utilisation d'une substance liant le CD28 dans la production d'une composition pharmaceutique à effet dose-dépendant
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
SI1680141T1 (sl) 2003-11-04 2010-12-31 Novartis Vaccines & Diagnostic Postopki terapije za trdne tumorje, ki izražajo CD-40 celično-površinski antigen
JP4746552B2 (ja) 2003-11-04 2011-08-10 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 自己免疫疾患および炎症性疾患ならびに臓器移植拒絶の処置のためのアンタゴニスト抗ｃｄ４０抗体の使用
ES2346978T3 (es) 2003-11-04 2010-10-22 Novartis Vaccines And Diagnostics, Inc. Uso de anticuerpos monoclonantes anti-cd40 antagonistas para el tratamiento del mieloma multiple.
WO2005044307A2 (fr) 2003-11-04 2005-05-19 Chiron Corporation Procedes de therapie pour des cancers lies a la cellule b
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
CA2544364A1 (fr) 2003-11-04 2005-05-19 Chiron Corporation Utilisation d'anticorps anti-cd40 antagonistes pour le traitement de la leucemie lymphocytique chronique
DE10352900A1 (de) 2003-11-11 2005-06-16 Tegenero Ag Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von B-CLL
US20050136055A1 (en) 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
KR101223373B1 (ko) 2003-12-25 2013-01-16 교와 핫꼬 기린 가부시키가이샤 항 ｃｄ４０ 항체의 변이체
US20060099203A1 (en) 2004-11-05 2006-05-11 Pease Larry R B7-DC binding antibody
JP5112863B2 (ja) 2004-07-01 2013-01-09 ノヴォ ノルディスク アー／エス ヒト抗−ｋｉｒ抗体
WO2006003179A2 (fr) 2004-07-01 2006-01-12 Novo Nordisk A/S Anticorps anti-kir humains
US20080057070A1 (en) 2004-11-04 2008-03-06 Chiron Corporation Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
DE102004063494A1 (de) 2004-12-23 2006-07-13 Tegenero Ag Antikörper
ES2374603T3 (es) 2005-01-06 2012-02-20 Novo Nordisk A/S Agentes de unión a kir y procedimientos de uso de los mismos.
JP5154949B2 (ja) 2005-01-06 2013-02-27 ノヴォ ノルディスク アー／エス ウイルス感染を治療するための組成物および方法
WO2006072625A2 (fr) 2005-01-06 2006-07-13 Novo Nordisk A/S Procedes et traitements combines anti-kir
US20070161644A1 (en) 2005-01-25 2007-07-12 Stockwell Brent R Erastin analogs and uses thereof
NZ560320A (en) 2005-01-25 2011-02-25 Prolexys Pharmaceuticals Inc Quinoxaline derivatives as antitumor agents
US8759490B2 (en) 2005-03-24 2014-06-24 Millennium Pharamaceuticals, Inc. Antibodies that bind OV064 and methods of use therefor
US8323645B2 (en) 2005-03-24 2012-12-04 Millennium Pharmaceuticals, Inc. Antibodies that bind OV064 and methods of use therefor
AU2006230099B2 (en) 2005-03-25 2012-04-19 Gitr, Inc. GITR binding molecules and uses therefor
US20060240006A1 (en) 2005-04-20 2006-10-26 Chishih Chu Novel antibody structures derived from human germline sequences
EP1874823B1 (fr) 2005-04-27 2016-01-13 Indiana University Research and Technology Corporation Anticorps de l'isoforme de l'antigene nucleaire des cellules proliferatives cancereuses specifiques (pcnacs) et leurs utilisations
PL2161336T5 (pl) 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
US7585960B2 (en) 2005-05-11 2009-09-08 Theramab Gmbh Nucleic acids encoding superagonistic anti-CD28 antibodies
JP5208730B2 (ja) 2005-05-18 2013-06-12 ノバルティス アーゲー Ｃｄ４０シグナル伝達によって媒介される増殖性障害の診断および治療のための方法
PL1889065T3 (pl) 2005-05-18 2013-12-31 Novartis Ag Metody diagnostyki i leczenia chorób posiadających składnik autoimmunologiczny i/lub zapalny
KR100694508B1 (ko) 2005-05-24 2007-03-13 울산대학교 산학협력단 Ｈｂｂｋ４항체를 포함하는 암 질환 치료용 약학조성물및 이를 이용한 암의 면역치료 방법
EP1885399B1 (fr) 2005-05-26 2010-10-20 Seattle Genetics, Inc. Anticorps anti-cd40 humanisés et procédés d'utilisation
CA2612241C (fr) 2005-07-01 2018-11-06 Medarex, Inc. Anticorps monoclonaux humains diriges contre un ligand de mort programmee de type 1(pd-l1)
JP2009517339A (ja) 2005-11-01 2009-04-30 ノバルティス アーゲー 抗ｃｄ４０抗体の使用
JP2009513712A (ja) 2005-11-01 2009-04-02 ノバルティス アーゲー 抗ｃｄ４０抗体の使用
TWI461436B (zh) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
NZ568015A (en) 2005-12-08 2012-03-30 Medarex Inc Human monoclonal antibodies to O8E
AU2006329944A1 (en) 2005-12-09 2007-07-05 Seattle Genetics, Inc. Methods of using CD40 binding agents
TW200811185A (en) 2005-12-22 2008-03-01 Prolexys Pharmaceuticals Inc Fused pyrimidones and thiopyrimidones, and uses thereof
BRPI0620264A2 (pt) 2005-12-22 2011-11-08 Prolexys Pharmaceuticals Inc quinazolonas aril-substituìdas e sua utilização
US20110008368A1 (en) 2006-01-13 2011-01-13 Board Of Regents, The University Of Texas System Methods of modulating the ox40 receptor to treat cancer
GEP20125628B (en) 2006-04-21 2012-09-10 Novartis Ag Pharmaceutical compositions containing antagonist anti-cd40 antibody
EP1854810A1 (fr) 2006-05-09 2007-11-14 PanGenetics B.V. Anticorps monoclonal anti CD40 humain déimmunisé et antagoniste dérivé de l'anticorps ch5D12
WO2007149476A2 (fr) 2006-06-19 2007-12-27 Trustees Of Columbia University In The City Of New York Déterminations de la mort cellulaire non apoptotique et leurs utilisations
KR100745488B1 (ko) 2006-07-04 2007-08-02 학교법인 울산공업학원 항-4-1ｂｂ 항체 및 화학 항암제를 포함하는 암 질환 예방및 치료용 약학 조성물
WO2008013987A2 (fr) 2006-07-27 2008-01-31 Prolexys Pharmaceuticals, Inc. Pipérazinylméthylquinazolinones et azépanylméthylquinazolinones à substitution n-alkyle
GB0620894D0 (en) 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
AU2007334264A1 (en) 2006-11-15 2008-06-26 Medarex, Inc. Human monoclonal antibodies to BTLA and methods of use
US20100189723A1 (en) 2007-01-11 2010-07-29 Peter Andreas Nicolai Reumert Wagtmann Anti-kir antibodies, formulations, and uses thereof
JP5357778B2 (ja) 2007-01-23 2013-12-04 ゼンコー・インコーポレイテッド 最適化ｃｄ４０抗体および前記を使用する方法
WO2008103470A2 (fr) 2007-02-21 2008-08-28 Trustees Of Columbia University In The City Of New York Composés létaux dépendants du signal de ras oncogénique
EP2121008A4 (fr) 2007-03-22 2010-03-31 Sloan Kettering Inst Cancer Utilisations de l'anticorps monoclonal 8h9
EP2703011A3 (fr) 2007-05-07 2014-03-26 MedImmune, LLC Anticorps anti-ICOS et leur utilisation dans le traitement de l'oncologie, la transplantation et les maladies auto-immunes
CN108314663B (zh) 2007-05-10 2022-05-13 多格伍德药品公司 芴、蒽、呫吨、二苯并环庚酮和吖啶的衍生物及其用途
KR20080107050A (ko) 2007-06-05 2008-12-10 울산대학교 산학협력단 항-ｃｄ１３７ 단일클론 항체를 포함하는 만성이식편대숙주 질환의 예방 또는 치료용 약학적 조성물
KR101586617B1 (ko) 2007-06-18 2016-01-20 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
CN101970003A (zh) 2007-11-09 2011-02-09 诺华有限公司 抗cd40抗体的应用
AR069747A1 (es) 2007-11-30 2010-02-17 Medarex Inc Conjugado anticuerpo monoclonal anti-b7h4- farmaco y metodos de utilizacion
CN102006890A (zh) 2007-12-04 2011-04-06 阿尔尼拉姆医药品有限公司 靶向脂质
EP2245065A1 (fr) 2008-01-23 2010-11-03 Xencor, Inc. Anticorps dirigés contre cd40 optimisés et leurs procédés d'utilisation
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
EP2279003A4 (fr) 2008-05-01 2013-04-03 Gtc Biotherapeutics Inc Anticorps anti-cd137 en tant qu'agent dans le traitement d'états inflammatoires
CA2729567C (fr) 2008-06-30 2018-04-24 Kyowa Hakko Kirin Co., Ltd. Anticorps anti-cd27
US8518410B2 (en) 2009-03-10 2013-08-27 Baylor Research Institute Fusion protein with HIV antigen
KR20110036618A (ko) 2008-07-16 2011-04-07 베일러 리서치 인스티튜트 극대화된 Ｇａｇ 및 Ｎｅｆ를 수지상 세포에 표적화시킴을 기본으로 하는 ＨＩＶ 백신
US20110097339A1 (en) 2008-07-18 2011-04-28 Domantis Limited Compositions monovalent for CD28 binding and methods of use
EP2700651B1 (fr) 2008-07-18 2019-04-10 Bristol-Myers Squibb Company Compositions monovalentes pour la liaison au CD28 et procédés d'utilisation
AR073459A1 (es) 2008-07-18 2010-11-10 Domantis Ltd Composiciones de dominios variables de anticuerpos monovalentes para la union de cd28 y metodos de uso
CA2736829C (fr) 2008-09-12 2018-02-27 Isis Innovation Limited Anticorps specifiques de pd-1 et leurs utilisations
JP5794917B2 (ja) 2008-09-12 2015-10-14 アイシス・イノベーション・リミテッドＩｓｉｓ Ｉｎｎｏｖａｔｉｏｎｌｉｍｉｔｅｄ Ｐｄ−１特異抗体およびその使用
PL2342226T3 (pl) 2008-09-26 2017-01-31 Dana-Farber Cancer Institute, Inc. Ludzkie przeciwciała anty-PD-1, PD-L1 i PD-L2 oraz ich zastosowania
WO2010042433A1 (fr) 2008-10-06 2010-04-15 Bristol-Myers Squibb Company Combinaison d'anticorps cd137 et d'anticorps ctla-4 pour le traitement de maladies prolifératives
EP2367553B1 (fr) 2008-12-05 2017-05-03 Novo Nordisk A/S Traitement combiné pour améliorer la cytotoxicité induite par les cellules nk
EP4209510B1 (fr) 2008-12-09 2024-01-31 F. Hoffmann-La Roche AG Anticorps anti-pd-l1 et leur utilisation pour améliorer la fonction des lymphocytes t
WO2010082912A1 (fr) 2009-01-15 2010-07-22 Avalon Pharmaceuticals Dérivés de composés aromatiques à noyaux multiples et utilisations comme agents anti-tumoraux
BRPI1008692B8 (pt) 2009-02-17 2021-05-25 Ucb Biopharma Sprl anticorpo antagonista tendo especificidade para ox40 humano, sequência de dna isolado, vetor de clonagem ou de expressão, célula hospedeira, processo para a produção do referido anticorpo, composição farmacêutica, uso do 5 referido anticorpo e proteína de fusão
GB0903325D0 (en) 2009-02-26 2009-04-08 Univ Aberdeen Antibody molecules
AU2010222942B2 (en) 2009-03-10 2013-01-10 Baylor Research Institute Anti-CD40 antibodies and uses thereof
ES2571235T3 (es) 2009-04-10 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para el tratamiento de un tumor sanguíneo que utiliza el anticuerpo anti-TIM-3
EP2993188B1 (fr) 2009-04-20 2020-08-19 Kyowa Kirin Co., Ltd. Anticorps anti-cd40 comprenant une igg2 ayant trois acide aminés mutés
WO2010132389A2 (fr) 2009-05-14 2010-11-18 University Of Maryland, Baltimore Procédés de traitement de cancers et de maladies associées à l'expression de 4-1bb (cd137)
IN2012DN00863A (fr) 2009-07-31 2015-07-10 Medarex Inc
PT3023438T (pt) 2009-09-03 2020-05-08 Merck Sharp & Dohme Anticorpos anti-gitr
WO2011031063A2 (fr) 2009-09-09 2011-03-17 울산대학교 산학협력단 Composition de prévention ou de traitement de troubles métaboliques contenant l'anticorps anti-4-1bb
NO2504364T3 (fr) 2009-11-24 2018-01-06
CA2781311C (fr) 2009-12-07 2019-03-12 The Board Of Trustees Of The Leland Stanford Junior University Methodes d'amplification d'un traitement a base d'anticorps anticancereux
ES2705015T3 (es) 2009-12-29 2019-03-21 Kyowa Hakko Kirin Co Ltd Anticuerpo anti-CD27
WO2011091078A2 (fr) 2010-01-19 2011-07-28 Xencor, Inc. Variants d'anticorps possédant une activité complémentaire accrue
KR20110085038A (ko) 2010-01-19 2011-07-27 울산대학교 산학협력단 항 ｃｄ137-항체 및 독소 결합물을 이용한 ｃｄ137 양성세포의 제거방법
US8785604B2 (en) 2010-02-18 2014-07-22 Effimune Anti-CD28 humanized antibodies
PH12018501083A1 (en) 2010-03-04 2019-02-18 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
NZ602020A (en) 2010-03-31 2014-05-30 Boehringer Ingelheim Int Anti-cd40 antibodies
US9028830B2 (en) 2010-04-08 2015-05-12 JN Biosciences, LLC Antibodies to CD122
US20120213771A1 (en) 2010-04-13 2012-08-23 Celldex Therapeutics Inc. Antibodies that bind human cd27 and uses thereof
NZ602892A (en) 2010-04-13 2014-08-29 Celldex Therapeutics Inc Antibodies that bind human cd27 and uses thereof
WO2011155607A1 (fr) 2010-06-11 2011-12-15 協和発酵キリン株式会社 Anticorps anti-tim-3
JP6023706B2 (ja) 2010-07-09 2016-11-09 アデュロ・バイオテック・ホールディングス・ヨーロッパ・ベスローテン・フエンノートシャップＡｄｕｒｏ Ｂｉｏｔｅｃｈ Ｈｏｌｄｉｎｇｓ， Ｅｕｒｏｐｅ Ｂ．Ｖ． Ｃｄ２７に対するアゴニスト抗体
WO2012027328A2 (fr) 2010-08-23 2012-03-01 Board Of Regents, The University Of Texas System Anticorps anti-ox40 et leurs procédés d'utilisation
SG10201912092VA (en) 2010-09-09 2020-02-27 Pfizer 4-1bb binding molecules
CA2812046A1 (fr) 2010-09-15 2012-03-22 Alnylam Pharmaceuticals, Inc. Agents a base d'arni modifies
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
BR112013012138B1 (pt) 2010-11-22 2022-02-22 Innate Pharma Sa Uso de um composto que inibe um receptor inibidor de célula natural killer (nkcir)
WO2012075111A1 (fr) 2010-11-30 2012-06-07 Novartis Ag Utilisation d'anticorps anti-cd40 en thérapie combinée contre des cancers associés aux cellules b
CA2824278C (fr) 2010-12-20 2022-09-20 The Rockefeller University Modulation d'anticorps agonistes anti-tnfr
WO2012109238A2 (fr) 2011-02-07 2012-08-16 President And Fellows Of Harvard College Procédés d'augmentation des réponses immunitaires à l'aide d'agents qui se lient directement à ire-1 et activent ire-1
JP5458188B2 (ja) 2011-02-17 2014-04-02 協和発酵キリン株式会社 抗ｃｄ４０抗体の高濃度製剤
GB201103955D0 (en) 2011-03-09 2011-04-20 Antitope Ltd Antibodies
PT2683406T (pt) 2011-03-11 2019-07-08 Beth Israel Deaconess Medical Ct Inc Anticorpos anti-cd40 e utilização dos mesmos
MX373443B (es) 2011-03-31 2020-05-20 Inst Nat Sante Rech Med Anticuerpos dirigidos contra icos y usos de los mismos.
EP2699598B1 (fr) 2011-04-19 2019-03-06 Pfizer Inc Combinaisons d'anticorps anti-4-1bb et d'anticorps induisant une cytotoxicité à médiation cellulaire dépendante d'un anticorps (adcc) pour le traitement du cancer
SI2699264T1 (en) 2011-04-20 2018-08-31 Medimmune Llc Antibodies and other molecules that bind b7-h1 and pd-1
US9475879B2 (en) 2011-04-21 2016-10-25 Bristol-Myers Squibb Company Antibody polypeptides that antagonize CD40
KR102030987B1 (ko) 2011-04-25 2019-11-11 다이이찌 산쿄 가부시키가이샤 항 ｂ７-ｈ３항체
ES2709654T3 (es) 2011-04-29 2019-04-17 Apexigen Inc Anticuerpos anti-CD40 y métodos de uso
ES2765874T3 (es) 2011-05-25 2020-06-11 Innate Pharma Sa Anticuerpos anti-KIR para el tratamiento de trastornos inflamatorios
WO2013006490A2 (fr) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Anticorps se liant spécifiquement à tim3
HRP20180858T1 (hr) 2011-07-11 2018-09-21 Glenmark Pharmaceuticals S.A. Protutijela koja se vežu na ox40 i njihove uporabe
WO2013025779A1 (fr) 2011-08-15 2013-02-21 Amplimmune, Inc. Anticorps anti-b7-h4 et leurs utilisations
KR101685262B1 (ko) 2011-08-23 2016-12-21 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 항-ｏｘ４０ 항체 및 이의 사용 방법
GB201115280D0 (en) 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
WO2013039954A1 (fr) 2011-09-14 2013-03-21 Sanofi Anticorps anti-gitr
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
US9422351B2 (en) 2011-11-03 2016-08-23 The Trustees Of The University Of Pennsylvania Isolated B7-H4 specific compositions and methods of use thereof
UA112203C2 (uk) 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
BR122020002414B1 (pt) 2012-03-15 2022-03-03 Janssen Biotech, Inc Uso de anticorpos anti-cd27 humanos
US9580398B2 (en) 2012-04-02 2017-02-28 The Trustees Of Columbia University In The City Of New York Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
AU2013267161A1 (en) 2012-05-31 2014-11-20 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
KR101549637B1 (ko) 2012-06-08 2015-09-03 국립암센터 신규한 Ｔｈ1 세포 전환용 에피토프 및 이의 용도
US9695133B2 (en) 2012-07-13 2017-07-04 The Trustees Of Columbia University In The City Of New York Quinazolinone-based oncogenic-RAS-selective lethal compounds and their use
US9268936B2 (en) 2012-07-27 2016-02-23 Mandiant, Llc Physical memory forensics system and method
WO2014022758A1 (fr) 2012-08-03 2014-02-06 Dana-Farber Cancer Institute, Inc. Anticorps de liaison double à agent unique anti-pd-l1 et pd-l2 et procédés d'utilisation
WO2014035474A1 (fr) 2012-08-30 2014-03-06 The General Hospital Corporation Compositions et méthodes de traitement du cancer
EP2892928B1 (fr) 2012-09-03 2018-05-30 INSERM - Institut National de la Santé et de la Recherche Médicale Anticorps anti-icos pour traiter la maladie du greffon contre l'hôte
LT2904011T (lt) 2012-10-02 2017-11-10 Bristol-Myers Squibb Company Anti-kir antikūnų ir anti-pd-1 antikūnų derinys, akirtas vėžio gydymui
WO2014057687A1 (fr) 2012-10-11 2014-04-17 第一三共株式会社 Conjugué anticorps-médicament
WO2014061277A1 (fr) 2012-10-19 2014-04-24 第一三共株式会社 Conjugué anticorps-médicament produit par liaison par l'intermédiaire d'un lieur ayant une structure hydrophile
US9789182B2 (en) 2012-10-23 2017-10-17 Bristol-Myers Squibb Company Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer
JPWO2014065402A1 (ja) 2012-10-26 2016-09-08 株式会社ペルセウスプロテオミクス 抗ヒトｃｄ４０モノクローナル抗体及びその利用
JP2016011258A (ja) 2012-10-26 2016-01-21 株式会社ペルセウスプロテオミクス 抗ヒトｃｄ４０モノクローナル抗体及びその利用
CN104918957B (zh) 2012-10-30 2018-11-16 埃派斯进有限公司 抗-cd40抗体及其使用方法
JP2016509582A (ja) 2012-12-19 2016-03-31 アンプリミューン， インコーポレイテッド 抗ヒトｂ７−ｈ４抗体およびその使用
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
EP3299391B1 (fr) 2013-03-14 2019-12-04 Genentech, Inc. Anticorps et immunoconjugués anti-b7-h4
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
US20140322236A1 (en) 2013-03-15 2014-10-30 Sdix, Llc Anti-human adora2a antibodies
WO2014140374A2 (fr) 2013-03-15 2014-09-18 Novo Nordisk A/S Anticorps monovalents anti-cd27
MD20180107A2 (ro) 2013-03-18 2019-06-30 Biocerox Products B.V. Anticorpi anti-CD134 (OX40) umanizaţi şi utilizarea acestora
US20160084839A1 (en) 2013-04-02 2016-03-24 Marisa Dolled-Filhart Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue
MX376808B (es) 2013-05-24 2025-03-07 Medimmune Llc Anticuerpos anti-b7-h5 y sus usos.
US9676853B2 (en) 2013-05-31 2017-06-13 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-1
SG10201708143QA (en) 2013-06-06 2017-11-29 Pf Medicament Anti-c10orf54 antibodies and uses thereof
WO2014209168A1 (fr) 2013-06-24 2014-12-31 Kim Ruslan Zynsonovich Communicateur automobile
GB201311487D0 (en) 2013-06-27 2013-08-14 Alligator Bioscience Ab Bispecific molecules
RU2016107426A (ru) 2013-08-02 2017-09-07 Адуро Байотек Холдингс, Юроуп Б.В. Комбинирование агонистов cd27 и ингибирование иммунных контрольных точек для стимуляции иммунитета
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
WO2015036394A1 (fr) 2013-09-10 2015-03-19 Medimmune Limited Anticorps contre pd-1 et leurs utilisations
WO2015051149A1 (fr) 2013-10-04 2015-04-09 The Trustees Of Columbia University In The City Of New York Analogues de sorafenib et leurs utilisations
ES2707057T3 (es) 2013-11-06 2019-04-02 Bristol Myers Squibb Co Combinación de anticuerpos anti-KIR y anti-CS1 para tratar el mieloma múltiple
EP3791870A1 (fr) 2013-12-02 2021-03-17 The Trustees of Columbia University in the City of New York Modulation de la ferroptose et traitement des troubles excitotoxiques
GB201322583D0 (en) 2013-12-19 2014-02-05 Alligator Bioscience Ab Antibodies
WO2015091655A1 (fr) 2013-12-20 2015-06-25 F. Hoffmann-La Roche Ag Polythérapie avec un anticorps anti-ang 2 et un agoniste cd40
EP3094332B1 (fr) 2014-01-15 2018-09-12 The Trustees of Columbia University in the City of New York Analogues carbonylés de l'érastine et leur utilisation
ES2783026T3 (es) 2014-02-04 2020-09-16 Pfizer Combinación de un antagonista de PD-1 y un agonista de 4-1BB para el tratamiento de cáncer
WO2015134988A1 (fr) 2014-03-07 2015-09-11 Bristol-Myers Squibb Company Procédé d'utilisation de polypeptides d'anticorps qui sont des antagonistes de cd40 pour traiter une affection intestinale inflammatoire (aii)
MX2016015181A (es) 2014-05-21 2017-05-25 Pfizer Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer.
DK3148579T3 (da) 2014-05-28 2021-03-08 Agenus Inc Anti-gitr antistoffer og fremgangsmåder til anvendelse deraf
WO2015181267A1 (fr) 2014-05-29 2015-12-03 Spring Bioscience Corporation Anticorps anti-b7-h3 et leurs utilisations diagnostiques
MA40074A (fr) 2014-05-30 2015-12-03 Univ Columbia Composés liant ras multivalents
WO2015188047A1 (fr) 2014-06-06 2015-12-10 University Of Maryland, Baltimore Anticorps monoclonaux anti-cd-137 présentant des capacités de liaison distinctes au fcγr pour le traitement d'un cancer ou d'une auto-immunité
AU2015271709B2 (en) 2014-06-06 2020-11-26 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
WO2015198147A1 (fr) 2014-06-23 2015-12-30 Theramab Llc Compositions et méthodes pour une immunothérapie efficace et sûre
CN106659852A (zh) 2014-07-09 2017-05-10 诺和诺德股份有限公司 机动化药物输送装置
CN105296433B (zh) 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
KR102443258B1 (ko) 2014-08-12 2022-09-14 엘리게이터 바이오사이언스 에이비 항 cd40 항체에 의한 병용 치료제
RU2017108173A (ru) 2014-08-14 2018-09-17 Ф.Хоффманн-Ля Рош Аг Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1
US20170233485A1 (en) 2014-08-18 2017-08-17 Biogen Ma Inc. Anti-cd40 antibodies and uses thereof
US20170247455A1 (en) 2014-08-22 2017-08-31 Bristol-Myers Squibb Company Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody
AU2015306621B2 (en) 2014-08-27 2021-05-06 Memorial Sloan Kettering Cancer Center Antibodies, compositions, and uses
CA2951604A1 (fr) 2014-08-29 2016-03-03 Pablo Umana Therapie combinatoire d'immunocytokines a variant de l'il -2 ciblees therapie tumorale et d'anticorps anti-pd-l1 humaine
CN113698488A (zh) 2014-09-12 2021-11-26 基因泰克公司 抗-b7-h4抗体及免疫缀合物
RU2017115315A (ru) 2014-10-03 2018-11-08 Дана-Фарбер Кэнсер Инститьют, Инк. Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
GB201419094D0 (en) 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-TIM-3-antibodies
AU2015340056A1 (en) 2014-10-27 2017-05-25 Agency For Science, Technology And Research Anti-TIM-3 antibodies
ES2772307T3 (es) 2014-10-28 2020-07-07 Childrens Univ Hospital Tuebingen Tratamiento de pacientes pediátricos con LLA-PCB con un anticuerpo anti-kir
HUE054075T2 (hu) 2014-10-29 2021-08-30 Seagen Inc CD40 elleni nem fukozilált antitestek adagolása és bevitele
WO2016070001A1 (fr) 2014-10-31 2016-05-06 Jounce Therapeutics, Inc. Méthodes de traitement d'états pathologiques avec des anticorps qui se lient à b7-h4
ES2763548T3 (es) 2014-11-06 2020-05-29 Hoffmann La Roche Anticuerpos anti-TIM3 y procedimientos de uso
WO2016094837A2 (fr) 2014-12-11 2016-06-16 Igenica Biotherapeutics, Inc. Anticorps anti-c10orf54 et leurs utilisations
WO2016106004A1 (fr) 2014-12-23 2016-06-30 Full Spectrum Genetics, Inc. Nouveaux composés de liaison anti-b7h3 et leurs utilisations
US20160200815A1 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
WO2017058716A1 (fr) 2015-09-28 2017-04-06 Vivace Therapeutics, Inc. Composés tricycliques
WO2017120445A1 (fr) * 2016-01-07 2017-07-13 The Broad Institute, Inc. Composés et des méthodes pour augmenter l'infiltration tumorale par des cellules immunitaires
WO2018118711A1 (fr) 2016-12-19 2018-06-28 The Trustees Of Columbia University In The City Of New York Inducteurs de ferroptose à petites molécules
CN108409737B (zh) 2017-02-10 2020-07-03 华东理工大学 4-甲氧基苯基取代四氢-β-咔啉哌嗪二酮类衍生物及其应用
WO2018218087A1 (fr) * 2017-05-24 2018-11-29 K-Gen, Inc. Méthodes de traitement du cancer
WO2019006005A2 (fr) * 2017-06-28 2019-01-03 The Regents Of The University Of California Procédés et compositions pour le traitement du mélanome

Also Published As

Publication number Publication date
AU2019287765A1 (en) 2021-01-07
CA3103629A1 (fr) 2019-12-19
WO2019241730A2 (fr) 2019-12-19
WO2019241730A8 (fr) 2020-02-06
CN112638375A (zh) 2021-04-09
US20210251994A1 (en) 2021-08-19
WO2019241730A3 (fr) 2020-03-12
EP3806848A2 (fr) 2021-04-21
JP2021528393A (ja) 2021-10-21
KR20210035805A (ko) 2021-04-01

Similar Documents

Publication Publication Date Title
MA52897A (fr) Diminution de l'activité immunitaire par modulation de facteurs de signalisation post-cellulaire
MA55805A (fr) Métodes de modulation de l'activité immunitaire
EP3718259A4 (fr) Décomposition de tâches par chaînage d'intelligence artificielle
FR24C1039I2 (fr) Compositions modulant l'expression de sod-1
EP3738385A4 (fr) Signalisation efficace basée sur des associations de paramètres de configuration
EP3897522A4 (fr) Compositions de microcapsules
EA202090019A1 (ru) Спироциклические индолины в качестве модуляторов il-17
EP3781173A4 (fr) Modulation de la réponse immunitaire par ciblage de l'activité du récepteur olfactif
EP3801752A4 (fr) Intelligence artificielle pour un raffermissement de la peau amélioré
EP3638779A4 (fr) Méthodes et compositions pour l'activation de la cytoxicité tumorale par le biais de lymphocytes t gamma-delta humains
MA50122A (fr) Conversion de contexte de session
EP3970375A4 (fr) Signalisation de dérivation de différence de vecteur de mouvement
MX2020004519A (es) Moduladores de la vía de estrés integrada.
EP3853365A4 (fr) Modulateurs de l'expression de pnpla3
MA51337A (fr) Inhibiteurs spiro exo-aza de l'interaction ménine-mll
EP3359556A4 (fr) Modulation de l'activité des cytokines gamma-c
PL3487491T3 (pl) Kompozycje do zwiększenia aktywności mózgu
EP3844748A4 (fr) Signalisation de paramètres spatiaux
IL263997A (en) Human-enzyme mediated depletion of cystine
EP3781207A4 (fr) Méthodes et compositions pour la croissance des cheveux par activation de l'autophagie
EP3897641C0 (fr) Traitement de troubles du mouvement
MA49827A (fr) Méthodes et compositions pour améliorer la santé de plantes et/ou le rendement de plantes
EP3766363A4 (fr) Composition permettant d'améliorer des problèmes de peau
EP3923972A4 (fr) Méthode de modulation de l'immunité par modulation de l'abcf1
EP3894418A4 (fr) Préparation de triiodosilanes